Arlin® 400 tablet: Each film-coated tablet contains Linezolid INN 400 mg.
Arlin® 600 tablet: Each film-coated tablet contains Linezolid INN 600 mg.
Arlin® Powder for Suspension: After reconstitution each 5 ml contains Linezolid INN 100 mg.
Arlin contains Linezolid, a synthetic antibacterial agent of the oxazolidinone class with bactericidal and bacteriostatic activity against Gram-positive pathogens.
Vancomycin-Resistant Enterococcus faecium infections; Nosocomial pneumonia (methicillin-susceptible and -resistant Staphylococcus aureus, Streptococcus pneumoniae); Complicated and uncomplicated skin and skin structure infections; Community-acquired pneumonia.
Complicated skin and skin structure infections / Pneumonia: Adults and adolescents (12 years and older): 600 mg IV or oral every 12 hours for 10 to 14 days. Pediatric patients (birth through 11 years): 10 mg/kg IV or oral every 8 hours for 10 to 14 days. Vancomycin-resistant Enterococcus: 600 mg every 12 hours for 14 to 28 days.
Monoamine oxidase inhibitors; adrenergic and serotonergic agents; tramadol; selective serotonin reuptake inhibitors (SSRIs).
Arlin is contraindicated in patients with known hypersensitivity to Linezolid or any of the excipients; patients taking any medicinal product which inhibits monoamine oxidases A or B.
Diarrhea, headache, nausea, vomiting, insomnia, constipation, rash, dizziness, and fever.
There are no adequate and well-controlled studies in pregnant women. Linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Myelosuppression (anemia, leukopenia, pancytopenia, thrombocytopenia) - complete blood counts should be monitored weekly; lactic acidosis; peripheral and optic neuropathy with long-term therapy; serotonin syndrome.
Store at temperature between 15°C and 30°C. Protect from light and moisture.